ACM Biolabs • Innovative medicines through next generation targeted delivery. • Versatile platform for infectious disease prevention and therapies. We are based in two world leading innovation hubs for biotechnology: Singapore and Switzerland. Embedded in a rich ecosystem of pharmaceutical companies, biotechs, and institutional and private investors, we believe this is a valuable success factor to advance our science and pipeline programs. Our experienced team with senior ex-pharma veterans provide a basis to attract talent, partners and investors. As a dedicated team combining pharmaceutical industry, biotech, and academic excellence we develop prophylactic treatment and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment based on our proprietary polymer based delivery platform technology. We believe in challenging the status quo of targeted delivery in medicines and we are revolutionizing the new medicines with ACM platform. We develop these transformative medicines to treat or prevent diseases in a safe and well tolerable way. _____ 1. Our delivery is targeted to antigen-presenting cells. These dendritic cells are best suited to educate the immune system in an elegant way against virus antigens. Therefore, only low amounts of payloads in ACMs are needed. 2. ACM delivery are only made of a few components, self-assemble and encapsulate proteins, peptides, and mRNA. That means an easy manufacturing process for vast amounts of bulk product. 3. Our payload is protected at refrigerator temperatures. We can store mRNA at 4°C making storage and transport much easier.
